Controversies in breast cancer: The mammalian target of rapamycin as a target for breast cancer therapy

Breast Cancer Research

Volumn 11, Issue SUPPL. 3, 2009, Pages

  Di Cosimo, Serena ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; LETROZOLE; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TEMSIROLIMUS; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMIDAZOLE DERIVATIVE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN SERINE THREONINE KINASE; QUINOLINE DERIVATIVE; SIGNAL PEPTIDE;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; DRUG EFFICACY; DRUG TARGETING; NONHUMAN; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMIDAZOLES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 77951915322     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2444     Document Type: Article

References (16)

1. Schmelzle T, Hall M. TOR, a central controller of cell growth. Cell 2000, 103:253-262. 10.1016/S0092-8674(00)00117-3, 11057898.
2. Jefferies H, Fumagalli S, Dennis PB. Rapamycin suppresses 5' TOP mRNA translation through inhibition of p70s6k. EMBO J 1997, 16:3693-3704. 1169993, 9218810, 10.1093/emboj/16.12.3693.
3. Gingras A, Gygi S, Raught B. Regulation of 4E-BP1 phosphorylation: a novel two-step mechanism. Genes Dev 1999, 13:1422-1437. 316780, 10364159, 10.1101/gad.13.11.1422.
4. Vivanco I, Sawyers C. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2:489-501. 10.1038/nrc839, 12094235.
5. Di Cosimo S, Seoane J, Guzman M. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the insulin like growth factor-1-receptor (IGF-1-R) inhibitor NVP-AEW-541: a mechanistic based anti-tumor strategy. J Clin Oncol 2005, 23(Suppl 16):3112.
6. Di Cosimo S, Scaltriti M, Val D. The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy. J Clin Oncol 2007, 25(Suppl 18):3511.
7. Carracedo A, Ma L, Teruya-Feldstein J. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 2008, 118:3065-3074. 2518073, 18725988.
8. Sarbassov DD, Ali SM, Sengupta S. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006, 22:159-168. 10.1016/j.molcel.2006.03.029, 16603397.
9. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091. 2680495, 18676830, 10.1158/0008-5472.CAN-07-6854.
10. Markman B, Atzori F, Pérez-García J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2009,
11. Tabernero J, Rojo F, Calvo E. Dose - and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008, 26:1603-1610. 10.1200/JCO.2007.14.5482, 18332469.
12. Ellard SL, Clemons M, Gelmon KA. Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 2009, 27:4536-4549. 10.1200/JCO.2008.21.3033, 19687332.
13. Baselga J, Semiglazov V, van Dam P. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol 2009, 27:2630-2637. 10.1200/JCO.2008.18.8391, 19380449.
14. Baselga J, Fumoleau P, Gil M. Phase II, 3 arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Preliminary results. J Clin Oncol 2004, 22(Suppl 14):544.
15. Chow LWS, Sun Y, Jassem J. Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006, 100(Suppl 1):6091.
16. André F, Campone M, Hurvitz SA. Multicenter phase I clinical trial of daily and weekly RAD001 in combination with weekly paclitaxel and trastuzumab in patients with HER2-overex-pressing metastatic breast cancer with prior resistance to trastuzumab. J Clin Oncol 2008, 26(Suppl 20):1003.